EIKEN CHEMICAL CO., LTD. (Code: 4549)
July 31, 2025
Financial Results for Q1 FY2025
2
Financial Results for Q1 FY2025
Executive Summary
-
External Environment
The impact of soaring global commodity prices, geopolitical risks, U.S. trade policies, and monetary policies of major countries
Continued rise in costs such as logistics and raw material procurement due to the depreciation of the yen and high crude oil prices
-
The Company's Business Results
Sales and profit increased year-on-year, driven mainly by strong performance in fecal immunochemical test (FIT) reagents, urinalysis and medical devices for overseas market.
- Other
Completion of new manufacturing building in Nogi Factory
Transfer of equity interests of consolidated subsidiary "EIKEN CHINA CO., LTD."
Initiatives to reinforcing earnings strength
Completion of the acquisition of treasury shares announced on October 31, 2024 (2 million shares)
Selected for the "FTSE Blossom Japan Index" for the first time
3
Q1 FY2024
Q1 FY2025
Amount of
Percentage
FY2025 Forecast
Results
Results
Change
of Change
Amount
Progress rate
Net sales
9,519
10,197
678
7.1%
42,200
24.2%
Cost of sales
5,566
6,094
528
9.5%
25,150
24.2%
Gross profit
3,953
4,103
150
3.8%
17,050
24.1%
SG&A expenses
3,369
3,302
(67)
(2.0%)
13,800
23.9%
Operating profit
583
800
217
37.2%
3,250
24.6%
Ordinary profit
641
813
172
26.8%
3,100
26.2%
Net profit
486
600
113
23.4%
3,770
15.9%
R&D expenses
1,049
973
(76)
(7.3%)
4,040
24.1%
Financial Results for Q1 FY2025
Consolidated Financial Results-YoY Change
Millions of yen
Increased revenue and profit year-on-year, driven primarily by strong sales in overseas markets
Expected to record an extraordinary gain of approximately 1.9 billion yen from the sale of subsidiary shares in the second quarter
4
Financial Results for Q1 FY2025
Sales Results by Region -YoY Change
Fecal immunochemical tests (FIT)
Immunological and serological excluding FIT
Urinalysis Microbiological
Clinical chemistry test
Equipment/ Food and
Environment Molecular test
Medical devices/Others
Q1 FY2024
Results
Q1 FY2025
Results
Amount of Change
Percentage of Change
Millions of yen
3,120
3,450
329
10.6%
13,640
25.3%
2,481
2,505
23
1.0%
9,680
25.9%
1,122
1,187
65
5.9%
4,740
25.0%
1,058
1,081
23
2.2%
4,900
22.1%
150
149
(1)
(0.8%)
610
24.4%
512
473
(38)
(7.5%)
1,860
25.4%
232
391
159
68.8%
2,440
16.0%
840
956
115
13.7%
4,330
22.1%
Total
9,519
10,197
678 7.1% 42,200 24.2%
Strong performance in overseas sales of FIT, urinalysis and medical devices
Sales of molecular test-related products increased due to increased demand for pertussis tests in Japan, and overseas growth slowed due to the impact of the shuttering of USAID compared to forecast.
5
FY2025 Forecast
Amount
Progress rate